{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:56:45Z","timestamp":1773046605693,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2639750","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:58:57Z","timestamp":1773043137000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A narrative review of considerations when assessing potential relationships between Guillain-Barr\u00e9 syndrome and vaccines"],"prefix":"10.1080","volume":"22","author":[{"given":"Sarah Elizabeth","family":"Williams","sequence":"first","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olympia Evdoxia","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["Thessaloniki, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Lino","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihua","family":"Liang","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Wu","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Hall-Murray","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Chilson","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Pfizer, Inc","place":["Dublin, Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932040-00005"},{"key":"e_1_3_2_3_1","unstructured":"National Institute of Neurological Disorders and Stroke. Guillain-Barr\u00e9 syndrome. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/guillain-barre-syndrome."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/513785"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/Wnl.0000000000200885"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-510x(02)00418-5"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24755"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1702.100856"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.51.4.1110"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70140-7"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf621"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1368706"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000509681"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12021"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02319-4"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.11.003"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx181"},{"key":"e_1_3_2_19_1","unstructured":"Kelly SP Zhang C Edwards T Graf L Thistle J Wu J Rubino H Begier E Russo L Lino M. Increasing incidence of Guillain-Barr\u00e9 syndrome in the United States among integrated delivery systems from 2017 to 2023: trends by vaccination status age and Charlson Comorbidity Index (CCI) score. IDWeek. Atlanta Georgia; 2025."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.01.028"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.300995"},{"key":"e_1_3_2_22_1","unstructured":"Kohl KS Bonhoeffer J Braun MM Chen R Duclos P Heijbel H Heininger U Loupi E Marcy SM The Brighton Collaboration. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. In: Henriksen K Battles JB Marks ES Lewin DI editors. Advances in patient safety: from research to implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb. p. 1\u201311. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK20507\/."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"e_1_3_2_24_1","first-page":"2181","article-title":"Polyarteritis nodosa reports to the Vaccine Adverse Event Reporting System (VAERS): implications for assessment of suspected vaccine-provoked vasculitis","volume":"31","author":"Begier EM","year":"2004","unstructured":"Begier EM, Langford CA, Sneller MC, Wise RP, Ball R, VAERS Working Group. Polyarteritis nodosa reports to the Vaccine Adverse Event Reporting System (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol. 2004;31:2181\u20132188.","journal-title":"J Rheumatol"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(14)78108-8"},{"key":"e_1_3_2_26_1","first-page":"77","article-title":"The utility of the World Health Organization-the Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children","volume":"26","author":"Tantikul C","year":"2008","unstructured":"Tantikul C, Dhana N, Jongjarearnprasert K, Visitsunthorn N, Vichyanond P, Jirapongsananuruk O. The utility of the World Health Organization-the Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children. Asian Pac J Allergy. 2008;26:77\u201382.","journal-title":"Asian Pac J Allergy"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.03037"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4515"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.142"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127291"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.27.24319702"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66280-z"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gloepi.2024.100145"},{"key":"e_1_3_2_34_1","unstructured":"Liang C Chilson E Wu J Kelly S Liu Q Dooling K Lino M Gessner B Begier E. Impact of background event rates on calculation of Guillain-Barr\u00e9 syndrome attributable risk in vaccine self-control case series analyses and implications for vaccine public health impact assessments. ISIRV. Iguazu Brazil; 2025."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.07.25327155"},{"key":"e_1_3_2_36_1","unstructured":"U.S. FDA. Abrysvo prescribing information US FDA; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/abrysvo."},{"key":"e_1_3_2_37_1","unstructured":"FDA. Arexvy FDA. 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/arexvy."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1985890"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7"},{"key":"e_1_3_2_40_1","unstructured":"MHRA. Abrysvo\u25bc (Pfizer RSV vaccine) and arexvy\u25bc (GSK RSV vaccine): be alert to a small risk of Guillain-Barr\u00e9 syndrome following vaccination in older adults. 2025. https:\/\/www.gov.uk\/drug-safety-update\/abrysvov-pfizer-rsv-vaccine-and-arexvyv-gsk-rsv-vaccine-be-alert-to-a-small-risk-of-guillain-barre-syndrome-following-vaccination-in-older-adults."},{"key":"e_1_3_2_41_1","volume-title":"Immunization safety review: influenza vaccines and neurological complications","author":"Stratton K","year":"2004","unstructured":"Stratton K, Dake WA, Wizemann T, McCormick MC. Immunization safety review: influenza vaccines and neurological complications. Washington (DC): National Academies Press; 2004."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1201.051007"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1985.04060100075026"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0588"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.013"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.6227"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207847"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8322"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66280-z"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111088"},{"key":"e_1_3_2_53_1","unstructured":"Melgar M. RSV vaccination in adults: work group interpretations. 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/06-RSV-Adult-Melgar-508.pdf."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2639750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:59:00Z","timestamp":1773043140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2639750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2639750"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2639750","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2639750"}}